CLEVELAND, Feb. 19, 2021 /PRNewswire/ -- ViewRay, Inc.
(Nasdaq: VRAY) announced today details relating to the release of
its fourth quarter and full year 2020 financial results.
ViewRay will hold a conference call to discuss results on
Thursday, March 4, 2021 at
4:30 p.m. ET / 1:30 p.m. PT. The dial-in numbers are (844)
277-1426 for domestic callers and (336) 525-7129 for international
callers. The conference ID number is 5976583. A live webcast of the
conference call will be available on the investor relations page of
ViewRay's corporate website at
http://investors.viewray.com/events-and-presentations/upcoming-events.
After the live webcast, a replay will remain available online on
the investor relations page of ViewRay's website, under "Financial
Events and Webinars", for 14 days following the call. In addition,
a telephonic replay of the call will be available until
March 11, 2021. The replay dial-in
numbers are (855) 859-2056 for domestic callers and (404) 537-3406
for international callers. Please use the conference ID number:
5976583.
About ViewRay®
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures, and markets
the MRIdian® MR-Guided Radiation Therapy System. MRIdian is built
upon a proprietary high-definition MR imaging system designed from
the ground up to address the unique challenges and clinical
workflow for advanced radiation oncology. Unlike MR systems used in
diagnostic radiology, MRIdian's high-definition MR was
purpose-built to address specific challenges, including beam
distortion, skin toxicity, and other concerns that potentially may
arise when high magnetic fields interact with radiation beams.
ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Private Securities Litigation
Reform Act. Statements in this press release that are not purely
historical are forward-looking statements. Such forward-looking
statements include, among other things, the rate of new orders,
upgrades, and installations, ViewRay's anticipated future operating
and financial performance, and ViewRay's conference calls to
discuss its quarterly results. Actual results could differ from
those projected in any forward-looking statements due to numerous
factors. Such factors include, among others, the ability to
commercialize MRIdian Linac System, demand for ViewRay's products,
the ability to convert backlog into revenue, the timing of delivery
of ViewRay's products, the timing, length, and severity of the
recent COVID-19 (coronavirus) pandemic, including its impacts
across our businesses on demand, operations and our global supply
chains, the results and other uncertainties associated with
clinical trials, the ability to raise the additional funding needed
to continue to pursue ViewRay's business and product development
plans, the inherent uncertainties associated with developing new
products or technologies, competition in the industry in which
ViewRay operates, and overall market conditions. For a further
description of the risks and uncertainties that could cause actual
results to differ from those expressed in these forward-looking
statements, as well as risks relating to ViewRay's business in
general, see ViewRay's current and future reports filed with the
Securities and Exchange Commission, including its Annual Report on
Form 10-K for the fiscal year ended December
31, 2019 and its Quarterly Reports on Form 10-Q, as updated
periodically with the company's other filings with the SEC. These
forward-looking statements are made as of the date of this press
release, and ViewRay assumes no obligation to update the
forward-looking statements, or to update the reasons why actual
results could differ from those projected in the forward-looking
statements, except as required by law.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/viewray-announces-conference-call-for-fourth-quarter-and-full-year-2020-financial-results-to-be-held-after-market-on-march-4-2021-301231863.html
SOURCE ViewRay, Inc.